3-(4-methanesulfonyl-phenyl)-propionic acid amide | 858214-97-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 3-(4-methanesulfonyl-phenyl)-propionic acid amide
• 英文别名: 3-(4-Methylsulfon-phenyl)-propionamid；3-(4-Methylsulfon-phenyl)-propionsaeure-amid；3-(4-Methansulfonyl-phenyl)-propionsaeure-amid；3-(4-Methylsulfonylphenyl)propanamide
• CAS: 858214-97-8
• 化学式: C₁₀H₁₃NO₃S
• 分子量: 227.284
• InChiKey: GHQLLTCGBRWGGR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.3
• 重原子数：
  15
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  85.6
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  3-(4-methanesulfonyl-phenyl)-propionic acid amide 在 氯仿 、 三氯氧磷 作用下， 生成 3-(4-(methylsulfonyl)phenyl)propanenitrile
  参考文献：
  名称：

  302. 砜类化疗剂。第四部分

  摘要：

  DOI：

  10.1039/jr9480001506
• 作为产物：
  描述：

  3-[4-(甲基磺酰基)苯基]丙酸 在 吡啶 、 氯化亚砜 、 氯仿 、 丙酮 作用下， 生成 3-(4-methanesulfonyl-phenyl)-propionic acid amide
  参考文献：
  名称：

  302. 砜类化疗剂。第四部分

  摘要：

  DOI：

  10.1039/jr9480001506

文献信息

• [EN] 5-SUBSTITUTED-PYRAZINE OR PYRIDINE GLUCOKINASE ACTIVATORS<br/>[FR] ACTIVATEURS DE LA GLUCOKINASE A BASE DE PYRAZINE OU DE PYRIDINE SUBSTITUEES EN POSITION 5
  申请人：HOFFMANN LA ROCHE

  公开号：WO2004052869A1

  公开（公告）日：2004-06-24

  The present invention provides a compound according to formula (I) where the substituent designations are provided in the specification. Pharmaceutical compositions comprising a compound according to formula (I) are also provided, said compounds being glucokinase activators which are useful in the treatment of type II diabetes.

  本发明提供了一种化合物，其化学式为（I），其中取代基的定义在说明书中提供。还提供了包括符合化学式（I）的化合物的药物组合物，这些化合物是葡萄糖激酶激活剂，对于治疗2型糖尿病是有用的。
• Compounds advantageous in the treatment of central nervous system diseases and disorders
  申请人：AurimMed Pharma, Inc.

  公开号：US10793515B2

  公开（公告）日：2020-10-06

  A series of novel amides showing broad pharmaceutical activity. Compounds described herein are effective as anticonvulsants, chemical countermeasures, and analgesics. Such compounds also show, neuroprotective/neuroreparative effects and activity against spinal muscular atrophy. Such pharmaceutically active compounds show utility in the treatment of central nervous system (“CNS”) diseases and disorders, such as anxiety, depression, insomnia, migraine headaches, schizophrenia, neurodegenerative diseases (e.g., Parkinson's disease, Alzheimer's, ALS, and Huntington's disease) spasticity, and bipolar disorder. Furthermore, such compounds may additionally find utility as analgesics (e.g., for the treatment of chronic or neuropathic pain) and as neuroprotective agents useful in the treatment of stroke(s), and/or traumatic brain and/or spinal cord injuries.

  一系列新型酰胺具有广泛的药物活性。本文所述化合物可作为抗惊厥剂、化学对策和镇痛剂。这些化合物还具有神经保护/神经恢复作用，并对脊髓性肌肉萎缩具有活性。这类药物活性化合物可用于治疗中枢神经系统（CNS）疾病和失调，如焦虑症、抑郁症、失眠症、偏头痛、精神分裂症、神经退行性疾病（如帕金森氏病、阿尔茨海默氏症、渐冻人症和亨廷顿氏病）、痉挛症和躁狂症。此外，这类化合物还可作为镇痛剂（如治疗慢性疼痛或神经性疼痛）和神经保护剂用于治疗中风和/或创伤性脑损伤和/或脊髓损伤。
• FUSED HETEROAROMATIC GLUCOKINASE ACTIVATORS
  申请人：F. HOFFMANN-LA ROCHE AG

  公开号：EP1341774B1

  公开（公告）日：2006-02-01
• 5-SUBSTITUTED-PYRAZINE OR -PYRIDINE GLUCOKINASE ACTIVATORS
  申请人：F. HOFFMANN-LA ROCHE AG

  公开号：EP1572670A1

  公开（公告）日：2005-09-14
• [EN] CARBAZOLE DERIVATIVES AND THEIR USE AS NEUROPEPTIDE Y5 RECEPTOR LIGANDS<br/>[FR] DERIVES DE CARBAZOLE ET LEUR UTILISATION EN TANT QUE LIGANDS DU RECEPTEUR DE NEUROPEPTIDE Y5
  申请人：ASTRAZENECA UK LTD

  公开号：WO2001007409A1

  公开（公告）日：2001-02-01

  The use of a compound of formula (I) in the manufacture of a medicament for the treatment, in a warm-blooded animal, of disorders mediated by the neuropeptide Y5 receptor wherein R1, R2, A, B, R3 and R4 are as defined within or a pharmaceutically acceptable salt, prodrug or solvate thereof, is described. Pharmaceutical compositions, methods and processes for preparation of compounds of formula (I) are also described.